Ten drugs have been chosen for price negotiations by the Centers for Medicare & Medicaid Services
Methadone dispensing up after 2020 without displacing use of buprenorphine
These low added therapeutic-rating drugs accounted for $19.3 billion or one-third of Medicare annual net spending in 2020
State-to-national Medicaid indices for psychiatrists' mental health services varied from 0.46 to 2.34 in Pennsylvania and Nebraska, respectively
For low-income adults, Medicare eligibility linked to reduction in percentage delaying or avoiding medical care due to cost
Under the law, Medicare will now be allowed to negotiate the cost of some drugs; vaccines will be free for Part D recipients
<p>Announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year</p>
<p>CMS says a final decision on coverage is not likely until next spring</p>